EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator

Yusuke Miyazaki iD, Kunihiro Iwamoto iD, Daiji Kambe iD, Yumiko Imadera, Isao Matsushita, Norio Ozaki iD

Psychiatry and Clinical Neurosciences · 2025

DOI: 10.1111/pcn.13888 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2025. Verfasst von Yusuke Miyazaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Automobile Driving, Orexin Receptor Antagonists, Hypnotics and Sedatives, Psychomotor Performance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taisho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sedative hypnotics can impair driving performance to a degree comparable to blood alcohol concentrations of 0.05%–0.08%. This study aimed to evaluate the residual effect of vornorexant, a novel orexin receptor antagonist, on next morning driving performance relative to a predefined clinically meaningful threshold.

Methods

Participants received 10 and 20 mg of vornorexant and placebo for eight consecutive nights and zopiclone on Days 1 and 8 in a four‐way crossover and double‐blind manner. Driving performance at 9‐h post‐dose was assessed measuring the standard deviation of the lateral position (SDLP) on Days 2 and 9 (days after single and repeated administration) using a validated driving simulator. Pharmacokinetics were also evaluated.

Results

Sixty‐one participants were randomized and 55 completed the study. The mean of drug‐placebo changes in SDLP (ΔSDLP) following vornorexant 10 and 20 mg were 0.767 and 2.132 cm on Day 2, and −0.422 and −0.040 cm on Day 9, respectively, whereas approximately 6 cm in zopiclone. All the upper bounds of the 90% confidence intervals of these changes were below the predefined clinically significant threshold. Symmetry analysis found no differences in the proportion of participants with ΔSDLP exceeding the threshold in either impairing or improving from 0 cm, at vornorexant 10 mg on Days 2 and 9 and 20 mg on Day 9. Pharmacokinetic analysis showed consistent plasma concentrations of vornorexant in single and repeated dosing.

Conclusions

Single and repeated administration of 10 and 20 mg vornorexant induced no clinically meaningful impairment in driving performance in healthy Japanese participants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Automobile DrivingOrexin Receptor AntagonistsHypnotics and SedativesPsychomotor PerformanceHumansMaleFemaleDouble-Blind MethodAdultCross-Over StudiesAzabicyclo CompoundsYoung AdultMiddle AgedPiperazinesComputer Simulation

Stichwörter der Autor:innen

cognitive functiondriving performancedriving simulatorinsomniavornorexant

Substanzen

Azabicyclo CompoundsOrexin Receptor AntagonistsHypnotics and SedativeszopiclonePiperazines

Autor:innen und Institutionen

  • Development Headquarters, Taisho Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
  • Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Yusuke Miyazaki, Kunihiro Iwamoto, Daiji Kambe, Norio Ozaki

Förderung

  • Taisho Pharmaceutical Co., Ltd.

Zitieren

APA

Miyazaki, Y., Iwamoto, K., Kambe, D., Imadera, Y., Matsushita, I., & Ozaki, N. (2025). Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13888

Vancouver

Miyazaki Y, Iwamoto K, Kambe D, Imadera Y, Matsushita I, Ozaki N. Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13888

BibTeX
@article{Miyazaki2025,
  author = {Miyazaki, Yusuke and Iwamoto, Kunihiro and Kambe, Daiji and Imadera, Yumiko and Matsushita, Isao and Ozaki, Norio},
  title = {Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2025},
  doi = {10.1111/pcn.13888}
}
Kostenlos starten →